Table 1.

Demographic and transplant-related characteristics of the study cohort

ParameterAll (n = 54)
Recipient age at HSCT, y (median, IQR) 57 (62) 
Recipient genre (M:F) 37:17 
Donor age, y (median, IQR) 41 (21.5) 
Donor genre (M:F) 39:15 
Underlying diagnosis, n (%)  
AML 27 (50) 
ALL 4 (7.4) 
AL nonspecific 2 (3.7) 
CML/CLL 2 (3.7) 
Lymphoma 4 (7.5) 
Myeloma 1 (1.9) 
MDPS/MDS/MPS 12 (22.2) 
Hemoglobinopathy 2 (3.7) 
Donor type, n (%)  
MUD 22 (40.7) 
MMUD 2 (3.7) 
MRD 9 (16.7) 
Haploidentical 21 (38.9) 
First transplantation, n (%) 49 (90.7) 
Conditioning with ATG, n (%) 39 (72.2) 
PTCy, n (%) 22 (40.7) 
No T-cell depletion, n (%) 53 (98.1) 
Cryopreservation, n (%) 43 (79.6) 
Stem cell source, n (%)  
BM 3 (5.5) 
PBSC 51 (94.4) 
CMV serostatus, n (%)  
D+/R+ 22 (40.7) 
D/R+ 12 (22.2) 
D+/R 7 (13) 
D/R 13 (24.1) 
Disease risk index, n (%)  
Low 4 (7.4) 
Intermediate 41 (75.9) 
High/very high 7 (13) 
NA 2 (3.7) 
ParameterAll (n = 54)
Recipient age at HSCT, y (median, IQR) 57 (62) 
Recipient genre (M:F) 37:17 
Donor age, y (median, IQR) 41 (21.5) 
Donor genre (M:F) 39:15 
Underlying diagnosis, n (%)  
AML 27 (50) 
ALL 4 (7.4) 
AL nonspecific 2 (3.7) 
CML/CLL 2 (3.7) 
Lymphoma 4 (7.5) 
Myeloma 1 (1.9) 
MDPS/MDS/MPS 12 (22.2) 
Hemoglobinopathy 2 (3.7) 
Donor type, n (%)  
MUD 22 (40.7) 
MMUD 2 (3.7) 
MRD 9 (16.7) 
Haploidentical 21 (38.9) 
First transplantation, n (%) 49 (90.7) 
Conditioning with ATG, n (%) 39 (72.2) 
PTCy, n (%) 22 (40.7) 
No T-cell depletion, n (%) 53 (98.1) 
Cryopreservation, n (%) 43 (79.6) 
Stem cell source, n (%)  
BM 3 (5.5) 
PBSC 51 (94.4) 
CMV serostatus, n (%)  
D+/R+ 22 (40.7) 
D/R+ 12 (22.2) 
D+/R 7 (13) 
D/R 13 (24.1) 
Disease risk index, n (%)  
Low 4 (7.4) 
Intermediate 41 (75.9) 
High/very high 7 (13) 
NA 2 (3.7) 

AL, acute leukemia; ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; ATG, antithymocyte globulin; BM, bone marrow; CLL, chronic lymphoblastic leukemia; CML, chronic myeloid leukemia; MDPS, myelodysplastic/myeloproliferative syndrome; MDS, myelodysplastic syndrome; MMUD, mismatched unrelated donor; MPS, myeloproliferative syndrome; MRD, matched related donor; MUD, matched unrelated donor; PBSC, peripheral blood stem cells; PTCy, posttransplant cyclophosphamide.

Close Modal

or Create an Account

Close Modal
Close Modal